SR33805
CAS No. 121345-64-0
SR33805 ( —— )
产品货号. M22404 CAS No. 121345-64-0
SR33805 是 Ca2+ 通道的有效拮抗剂(在去极化和极化条件下 EC50 分别为 4.1 nM 和 33 nM)。SR33805 的急性治疗恢复了 MI 改变的细胞缩短,而不影响 Ca(2+) 瞬态振幅,表明MI 肌细胞中肌丝 Ca(2+) 敏感性。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥591 | 有现货 |
|
| 10MG | ¥979 | 有现货 |
|
| 25MG | ¥1628 | 有现货 |
|
| 50MG | ¥2334 | 有现货 |
|
| 100MG | ¥3123 | 有现货 |
|
| 200MG | ¥4203 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥738 | 有现货 |
|
生物学信息
-
产品名称SR33805
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述SR33805 是 Ca2+ 通道的有效拮抗剂(在去极化和极化条件下 EC50 分别为 4.1 nM 和 33 nM)。SR33805 的急性治疗恢复了 MI 改变的细胞缩短,而不影响 Ca(2+) 瞬态振幅,表明MI 肌细胞中肌丝 Ca(2+) 敏感性。
-
产品描述SR33805 is a potent antagonist of Ca2+ channel(EC50s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively)Acute treatment with SR33805 restored the MI-altered cell shortening without affecting the Ca(2+) transient amplitude, suggesting an increase of myofilament Ca(2+) sensitivity in MI myocytes.?Indeed, a SR33805-induced sensitization of myofilament activation was found to be associated with a slight increase in myosin light chain-2 phosphorylation and a more significant decrease on troponin I (TnI) phosphorylation.?Decreased TnI phosphorylation was related to inhibition of protein kinase A activity by SR33805.?Finally, administration of a single intra-peritoneal bolus of SR33805 (20 mg/kg) improved end-systolic strain and fractional shortening of MI hearts.
-
体外实验SR33805 (0.01-10 μM; 3 d) inhibits growth factor-induced proliferation of SMC (0.2050<0.46 μM) in a dose-dependent manner.SR33805 (10 μM; 10 min) restores the myocardial infarction (MI)-altered cell shortening without affecting the Ca2+ transient amplitude.SR33805 (10 μM) decreases the activity of recombinant PKA. Cell Viability Assay Cell Line:Smooth muscle cells (SMC)Concentration:0.01, 0.1, 1, 10 μM Incubation Time:3 days Result:Inhibited in a dose-dependent manner FCS-, bFGF and PDGF-induced proliferation of porcine SMC with IC50s of 0.26±0.08, 0.46±0.1 and 0.20±0.04 μM, respectively.
-
体内实验SR33805 (20 mg/kg; a single i.p.) improves end-systolic strain and fractional shortening of MI hearts in rats.SR33805 (5 mg/kg/day; p.o. for 38 d) significantly reduces intimal hyperplasia in pigs. Animal Model:Male Wistar rats (5 weeks) are subjected to coronary artery ligature Dosage:0.2, 2, 20 mg/kg Administration:A single i.p. injection Result:Increased significantly both end-systolic strain (ESS) and fractional shortening (FS) by about +38 and +26%, respectively at the dose of 20 mg/kg.
-
同义词——
-
通路GPCR/G Protein
-
靶点Calcium Channel
-
受体Calcium Channel
-
研究领域——
-
适应症——
化学信息
-
CAS Number121345-64-0
-
分子量564.74
-
分子式C32H40N2O5S
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : ≥ 100 mg/mL (177.07 mM)
-
SMILESCOc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)n(C)c3ccccc23)cc1OC
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Mou YA, et, al. Beneficial effects of SR33805 in failing myocardium. Cardiovasc Res. 2011 Aug 1; 91(3): 412-9.
产品手册
关联产品
-
Ticolubant
Ticolubant is orally active leukotriene B4 antagonist with high affinity for the human neutrophil LTB4 receptor (Ki = 0.78 nM), blocks LTB4-induced Ca2+ migration with an IC50 of 6.6 ± 1.5 nM, and shows topical anti-inflammatory activity in a mouse model of skin inflammation.
-
Nisoldipine
Nisoldipine(BAY-k 5552; Sular)是高效特异的L型Cav1.2通道阻断剂,IC50为10 nM。
-
A-1048400
一种新型有效、选择性、口服活性的 N 型和 T 型钙通道阻滞剂,IC50 分别为 1.4 和 1.2 uM。
021-51111890
购物车()
sales@molnova.cn

